Paul Lockman

Dr. Paul Lockman

Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2015 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
TYTianzhi Yang
Tianzhi Yang
PMPaige Martin
Paige Martin
BFBrittany Fogarty
Brittany Fogarty
ABAlison Brown
Alison Brown
KSKayla Schurman
Kayla Schurman
Shuhua BaiShuhua Bai
Shuhua Bai

1 December 2004 in Journal of Drug Targeting
Verified
Journal Article
Closed access
Paul LockmanPaul Lockman
Paul Lockman
JKJoanna M. Koziara
Joanna M. Koziara
RMRussell J. Mumper
Russell J. Mumper
DADavid D. Allen
David D. Allen
The blood-brain barrier (BBB) presents both a physical and electrostatic barrier to limit brain permeation of therapeutics. Previous work has demonstrated that nanoparticles (NPs) overcome the physical barrier, but there is little known regarding the effect of NP surface charge on BBB function. Therefore, this work evaluated: (1) effect of neutral, anionic and cationic charged NPs on BBB integrity and (2) NP brain permeability. Emulsifying wax NPs were prepared from warm oil-in-water microemulsion precursors using neutral, anionic or cationic surfactants to provide the corresponding NP surface charge. NPs were characterized by particle size and zeta potential. BBB integrity and NP brain permeability were evaluated by in situ rat brain perfusion. Neutral NPs and low concentrations of anionic NPs were found to have no effect on BBB integrity, whereas, high concentrations of anionic NPs and cationic NPs disrupted the BBB. The brain uptake rates of anionic NPs at lower concentrations were superior to neutral or cationic formulations at the same concentrations. (1) Neutral NPs and low concentration anionic NPs can be utilized as colloidal drug carriers to brain, (2) cationic NPs have an immediate toxic effect at the BBB and (3) NP surface charges must be considered for toxicity and brain distribution profiles.

1 December 2010 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Paul LockmanPaul Lockman
Paul Lockman
RMRajendar K. Mittapalli
Rajendar K. Mittapalli
KTKunal S. Taskar
Kunal S. Taskar
VRVinay Rudraraju
Vinay Rudraraju
BGBrunilde Gril
Brunilde Gril
QSQuentin R. Smith
Quentin R. Smith
Purpose: Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten to compromise gains made in systemic chemotherapy. The blood–tumor barrier (BTB) is compromised in many brain metastases; however, the extent to which this influences chemotherapeutic delivery and efficacy is unknown. Herein, we answer this question by measuring BTB passive integrity, chemotherapeutic drug uptake, and anticancer efficacy in vivo in two breast cancer models that metastasize preferentially to brain. Experimental Design:Experimental brain metastasis drug uptake and BTB permeability were simultaneously measured using novel fluorescent and phosphorescent imaging techniques in immune-compromised mice. Drug-induced apoptosis and vascular characteristics were assessed using immunofluorescent microscopy. Results: Analysis of over 2,000 brain metastases from two models (human 231-BR-Her2 and murine 4T1-BR5) showed partial BTB permeability compromise in greater than 89% of lesions, varying in magnitude within and between metastases. Brain metastasis uptake of 14C-paclitaxel and 14C-doxorubicin was generally greater than normal brain but less than 15% of that of other tissues or peripheral metastases, and only reached cytotoxic concentrations in a small subset (∼10%) of the most permeable metastases. Neither drug significantly decreased the experimental brain metastatic ability of 231-BR-Her2 tumor cells. BTB permeability was associated with vascular remodeling and correlated with overexpression of the pericyte protein desmin. Conclusions: This work shows that the BTB remains a significant impediment to standard chemotherapeutic delivery and efficacy in experimental brain metastases of breast cancer. New brain permeable drugs will be needed. Evidence is presented for vascular remodeling in BTB permeability alterations. Clin Cancer Res; 16(23); 5664–78. ©2010 AACR.

1 January 2002 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
Paul LockmanPaul Lockman
Paul Lockman
RMR. J. Mumper
R. J. Mumper
Mansoor A. KhanMansoor A. Khan
Mansoor A. Khan
DAD. D. Allen
D. D. Allen
Nanoparticles (NP) are solid colloidal particles ranging in size from 1 to 1000 nm that are utilized as drug delivery agents. The use of NPs to deliver drugs to the brain across the blood-brain bar...

1 September 2004 in Journal of Controlled Release
Verified
Journal Article
Closed access
JKJoanna M. Koziara
Joanna M. Koziara
Paul LockmanPaul Lockman
Paul Lockman
DADavid D. Allen
David D. Allen
RMRussell J. Mumper
Russell J. Mumper

1 December 2003 in Journal of Controlled Release
Verified
Journal Article
Closed access
Paul LockmanPaul Lockman
Paul Lockman
MOMoses O Oyewumi
Moses O Oyewumi
JKJoanna M Koziara
Joanna M Koziara
KRKaren E Roder
Karen E Roder
RMRussell J Mumper
Russell J Mumper
DADavid D Allen
David D Allen